33 2 Vol. 33 No. 2 2012 4 Journal of Jinan University Medicine Edition Apr. 2012 TNF-α IL-6 IL-1 1 2 1 3 2 2 2 1. 510630 2. 510632 3. 510630 NASH TNF-α 6 IL-6 1 IL-1 NASH NASH 16 HE O ELISA TNF-α IL-6 IL-1 TC LDL TC TG TNF-α IL-6 IL-1 P < 0. 01 TNF-α IL-6 IL-1 P < 0. 01 P < 0. 05 TG TC TG P < 0. 01 NASH TNF-α IL-6 IL-1 R285. 5 A 1000-9965 2012 02-0161 - 06 Effects of soothing liver and invigorating spleen recipes of TCM on hepatic inflammatory cytokines of rats with nonalcoholic steatosishepatitis JIN Ling 1 YANG Qin-he 2 ZHANG Yu-pei 2 WANG Wen-jing 2 HAN Li 1 CHEN You-peng 3 FENG Gao-fei 2 HE Xiu-min 2 ZHAO Ya-feng 2 SHEN Can-hong 2 YANG Xiao-lei 2 LI Guang-qiu 2 YAN Hai-zhen 2 HUANG Jin 2 1. Department of Traditional Chinese Medicine the First Affiliated Hospital Jinan University Guangzhou 510630 China 2. Department of Traditional Chinese Medicine Medcial college Jinan University Guangzhou 510632 China 3. Department of Infectious Disease the First Affiliated Hospital Jinan University Guangzhou 510630 China Abstract Aim To investigate the effects of soothing liver and invigorating spleen recipes on the levels of inflammatory cytokines in liver tissue of rats with nonalcoholic steatosishepatitis NASH and to 2011-10 - 18 30973694 091055930 1981-1961 - Tel 020-85226197 E-mail tyangqh@ jnu. edu. cn
162 33 explore the mechanisms of the anti-nash effect of the drugs. Methods The models of NASH rats were established with high fat diet then the rats were fed with soothing liver recipes invigorating spleen recipes and integrated recipes respectively in diferent groups. The rats were sacrificed after 16 weeks' medication blood and liver samples were collected for TC and TG test pathomorphology analysis and TNF-α IL-1 and IL-6 determination. Results In these model groups the level of TC and TG in the serum and liver tissue the level of TNF-α IL-1 and IL-6 in liver tissue in the model group were increased significantly P < 0. 01 and the fatty degeneration in hepatocytes in model group were more obvious. In these model groups the levels of TNF-α IL-1 and IL-6 in liver tissue were decreased significantly in the highdose invigorating spleen group and the high-dose integrated group P < 0. 05 P < 0. 01 the level of TG in serum and TC TG in liver tissue were decreased significantly in the high-dose integrated group P < 0. 01. Conclusion The Soothing liver and invigorating spleen recipes have certain therapeutic effects on rats with NASH the mechanisms may be their decreasing blood-lipoids liver lipids levels and TNF-α IL-1 and IL-6 levels in liver tissue. Key words nonalcoholic steatosishepatitis soothing liver and invigorating spleen recipes inflammatory cytokines rats nonalcoholic steatosishepatitis NASH non-alcoholic fatty liver disease NAFLD 26 60% ~ 80% 12 h non-alcoholic simple fatty liver NAFL g 5 g 5 g 6 g 5 g 5 g 1-2 NASH 3 g 2 15 g NASH 15 g 15 g 9 g 6 g 15 g 6 g 12 g 9 g 9 3 insulin resistance IR TNF-α 1002241S 3-5 NAFLD PI3Kp85α Kupffer ERK1 /2 p38mapk NF-κBp65 NAFLD 7. 8 pg / ml E3720-1101-1 IL-6 IL-1 ELISA NASH NASH 30 pg /ml R110418-06A 1 1. 1 1 SPF SD 80 200 ± 20 g 9. 6 SCXK 2008-0020 2008A020 22 ~ 2 1 6 6 3 3 TNF-α ELISA R110407-07A 1. 2 1 g kg d - 1
2 TNF-α IL-6 IL-1 163 3. 2 g kg d - 1 0. 5 cm 10% 30. 0 g kg d - 1 3 μm 10. 0 g kg d - 1 35. 7 g kg d - 1 0. 5 cm 0. 5 cm - 80 11. 9 g kg d - 1 O 10 3 2 NASH TC 3-5 TG HDL LDL 0. 1 g 0. 9 ml 88% 10% 1. 5% 0. 5% 10 ml /kg TC TG 2 1 1. 4 1 16 1. 3 HE 1 cm 4 3 000 r /min 10 min SPSS 13. 0 ± x 珋 ± s 12 h One-Way ANOVA P < 0. 05 3% 0. 1 ml /100 g 2 0. 5 cm 2. 1 1 TNF-α IL-6 IL-1 TNF-α 8 4 IL-1 IL-6 P < 0. 01 10% 5 ml TNF-α IL-1 IL-6 4 3 000 r /min 10 min - 80 TNF-α IL-1 IL-6 ELISA TNF-α IL-1 IL- P < 0. 01 P < 6 0. 05 1 2 0. 5 cm NASH 1 cm 0. 5 cm 1 TNF-α IL-1 IL-6 x 珔 ± s ρg ml - 1 n ρ TNF - α ρ IL - 1 ρ IL - 6 8 9 187. 28 ± 3 634. 79 8 833. 07 ± 1 593. 06 14 799. 16 ± 6 564. 83 8 14 538. 34 ± 4 384. 53 1 11 389. 65 ± 725. 7 1 24 708. 37 ± 3 855. 17 1 8 11 485. 77 ± 3 321. 18 10 345. 67 ± 516. 21 19 439. 86 ± 6 884. 74 8 13 509. 32 ± 4 001. 7 10 445. 63 ± 1 860. 84 19 089. 17 ± 6 598. 27 8 10 477. 07 ± 2 774. 98 3 10 138. 07 ± 454. 8 3 17 325. 13 ± 3 926. 59 3 8 13 387. 28 ± 3 408. 9 10 565. 24 ± 550. 29 19 615. 75 ± 3 926. 67 8 9 294. 39 ± 4 715. 72 2 9 392. 03 ± 1 643. 07 2 15 415. 75 ± 8 438. 11 2 8 10 276. 62 ± 4 270. 55 3 10 984. 40 ± 698. 02 17 080. 45 ± 4 851. 09 3 1 P < 0. 01 2 P < 0. 01 3 P < 0. 05.
164 33 2. 2 2 HE NASH 1 2 O 200 1 HE 200 2. 3 TC LDL P < 0. 01 TG P < 0. 01 TG P < 0. 05 NASH TG 2 2. 4 3 TC TG P < 0. 01 O TC TG TG P < 0. 01 TG P < 0. 05 TG
2 TNF-α IL-6 IL-1 165 2 TC TG HDL LDL x 珔 ± s mmol L - 1 n TC TG HDL - C LDL - C 10 1. 42 ± 0. 29 0. 56 ± 0. 27 0. 67 ± 0. 24 0. 30 ± 0. 11 10 3. 82 ± 0. 91 1 0. 83 ± 0. 26 0. 63 ± 0. 16 0. 81 ± 0. 27 1 10 3. 40 ± 0. 77 0. 54 ± 0. 18 0. 53 ± 0. 13 0. 72 ± 0. 25 10 4. 15 ± 0. 67 0. 60 ± 0. 19 0. 59 ± 0. 08 0. 92 ± 0. 17 10 3. 67 ± 1. 24 0. 46 ± 0. 13 3 0. 68 ± 0. 12 0. 73 ± 0. 23 10 3. 90 ± 0. 82 0. 72 ± 0. 23 0. 69 ± 0. 20 0. 98 ± 0. 30 10 2. 76 ± 0. 48 0. 45 ± 0. 14 2 0. 52 ± 0. 07 0. 64 ± 0. 23 10 3. 02 ± 0. 47 0. 43 ± 0. 09 2 0. 67 ± 0. 15 0. 52 ± 0. 09 1 P < 0. 01 2 P < 0. 01 3 P < 0. 05. 3 TC TG x 珔 ± s mmol L - 1 n TC TG 10 0. 90 ± 0. 14 0. 75 ± 0. 38 10 11. 86 ± 1. 29 1 6. 17 ± 1. 83 1 10 10. 29 ± 1. 49 5. 08 ± 1. 83 3 10 9. 87 ± 1. 88 3. 40 ± 1. 12 10 10. 51 ± 0. 96 3. 18 ± 1. 96 3 10 10. 01 ± 2. 09 3. 38 ± 1. 48 10 9. 17 ± 1. 02 2 2. 54 ± 0. 74 2 10 10. 37 ± 1. 28 2. 53 ± 0. 72 2 1 P < 0. 01 2 P < 0. 01 3 P < 0. 05. 3 13-14 NASH NAFLD NASH NASH 7 NASH < 20 g /d TNF-α IL-1 IL-6 8 15 9 NASH NASH NASH cytokine CK NAFLD NASH NASH CK TNF-α IL-1 IL-6 IL-12 IL-18 10 11 NAFLD T1 helper T1 cell Th1 NASH 12 NASH TNF-α IL-6 IL-1 NASH NAFLD
166 33 NF-кBp65 kupffer p38mapk J. 2009 27 2 141-147. 6. M. 3-5 1995 114-115 178-179. 7 CLARK J M DIEHL A M. Defining nonalocolic fatty liver disease implications for epidemiologic studies J. NASH TNF-α IL-1 Gastroenterology 2003 124 1 248-250. IL-6 8 HUBSCHER S G. Histological assessment of non-alcoholic fatty liver disease J. Histopathology 2006 49 5 450-465. NASH NASH 9 DAP C P JAMES O F W. Steatohepatitis A tale of two hits J. Gastroenterology 1998 114 4 842-845. 10 CRAIG J SH IRISH B ION D et al. Cytokines in alcoholic liver disease J. Semin Liver Dis 1999 19 2 NASH NAFLD 205-219. 11 MCCLAIN C J MOKSHAGUNDAM S P BARVE S S et al. Mechanisms of non-alcoholic steatohepatitis J. Alcohol 2004 34 1 67-79. 1 GREENFIELD V CHEUNG O SANYAL A J. Recent advances in nonalcoholic fatty liver disease J. Curr Opin Gastroenterol 2008 24 3 320-327. 2 FARRELL G C LARTER C Z. Nonalcoholic fatty liver disease from steatosis to cirrhosis J. Hepatology 2006 43 2 Suppl 1 S99 - S112. 3. 14 MARRA F BERTTOLANI C. Adipokines in liver diseases J. Hepatology 2009 50 3 957-969. J. 2009 25 1 62-67. 15. 4. -α 6 C PI3Kp85α kupffer ERK1 /2 J. J. 2010 25 4 322-324. 2007 23 8 1551-555. 5. 12. J. 2009 17 30 3118-3122. 13 CHOI S DIEHL A M. Role of inflammation in nonalcoholic steatohepatitis J. Curr Opin Gastroenterol 2005 21 6 702-707.